Traumatic Brain Injury(TBI) Pipeline Insights

DelveInsight’s, “Traumatic Brain Injury Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Traumatic Brain Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Traumatic Brain Injury Understanding

Traumatic Brain Injury Overview

Traumatic brain injury (TBI) is a major global health concern caused by external mechanical forces, including direct impact, rapid acceleration-deceleration, or penetrating head injuries, resulting in temporary or permanent impairment of brain function, disability, or death. TBIs are broadly classified into penetrating (open) injuries, in which an object breaches the skull and directly damages brain tissue, and nonpenetrating (closed) injuries, where external force causes the brain to move within an intact skull, commonly due to falls, motor vehicle accidents, sports injuries, blast exposure, or blunt trauma. Brain injury may be primary, occurring at the time of trauma, or secondary, developing over hours to weeks through progressive pathological processes. Based on clinical presentation and the Glasgow Coma Scale (GCS), TBI is categorized as mild (GCS 14–15), moderate (GCS 9–12), or severe (GCS 3–8), with mild TBI (concussion) accounting for more than 90% of cases. Falls are the leading cause of TBI, particularly among children and older adults, followed by motor vehicle collisions, sports- and work-related injuries, and assaults, while penetrating and blast-related injuries represent the most severe and life-threatening forms of head trauma. Diffuse axonal injury (DAI), resulting from rapid acceleration-deceleration without direct impact, is another serious subtype associated with substantial neurological impairment.

Traumatic brain injury (TBI) presents with a wide range of physical, cognitive, behavioral, emotional, and sensory symptoms that may appear immediately after injury or evolve during recovery, with severity varying according to the extent of brain damage. Common physical manifestations include headache, dizziness, confusion, fatigue, and irritability, while severe symptoms requiring immediate medical attention include persistent headache, seizures, blurred or double vision, unequal pupils, cerebrospinal fluid leakage from the nose or ears, recurrent vomiting, slurred speech, limb weakness, and impaired balance. Cognitive and behavioral symptoms include loss or alteration of consciousness, reduced alertness, disorientation, memory and concentration deficits, impaired decision-making, sleep disturbances, and emotional changes such as anxiety, depression, agitation, and irritability. Sensory disturbances, including vertigo, impaired coordination, visual changes, tinnitus, altered taste, and increased sensitivity to light or sound, are also common. In children, TBI may be more difficult to identify due to limited communication abilities and often presents as changes in feeding habits, inconsolable crying, reduced attention, loss of interest in activities, sleep disturbances, vomiting, seizures, regression of developmental milestones, impaired balance, or persistent behavioral changes, emphasizing the importance of early recognition and prompt clinical evaluation.

Traumatic brain injury (TBI) can occur at any age, but older adults (≥65 years) and males are at the highest risk. Older adults experience the greatest rates of TBI-related hospitalization and mortality, primarily due to falls, while males are more likely to sustain severe injuries because of greater involvement in high-risk activities. Falls are the leading cause of TBI, followed by blunt trauma, motor vehicle collisions, assaults, and blast-related injuries. These mechanisms can cause focal or diffuse brain damage, including diffuse axonal injury (DAI), with penetrating and blast injuries often resulting in the most severe neurological damage and long-term disability.

Traumatic brain injury (TBI) involves primary and secondary injury mechanisms that contribute to immediate and progressive neurological damage. Primary injury occurs at the time of trauma, causing skull fractures, cerebral contusions, hematomas, and diffuse axonal injury (DAI). Secondary injury develops over hours to days and is driven by hypoxia, elevated intracranial pressure (ICP), excitotoxicity, oxidative stress, neuroinflammation, and cerebral edema, leading to further neuronal damage. Increased ICP reduces cerebral perfusion, resulting in cerebral ischemia and, in severe cases, life-threatening brain herniation and respiratory failure.

The diagnosis of traumatic brain injury (TBI) requires a comprehensive and timely approach that combines clinical evaluation, neuroimaging, laboratory investigations, and standardized decision tools to determine injury severity and guide management. Initial assessment includes a detailed neurological examination to evaluate consciousness, cognitive function, cranial nerves, motor and sensory function, coordination, and behavior. Non-contrast computed tomography (CT) is the first-line imaging modality for detecting acute intracranial injuries, while magnetic resonance imaging (MRI) is more sensitive for identifying subtle lesions, including diffuse axonal injury (DAI). Clinical decision rules, such as the Canadian CT Head Rule (CCHR), New Orleans Criteria (NOC), and the Pediatric Emergency Care Applied Research Network (PECARN) algorithm, help identify patients requiring imaging while reducing unnecessary CT use. Laboratory tests, including complete blood count, metabolic profile, coagulation studies, and blood typing, are performed when clinically indicated, particularly in patients with severe trauma or bleeding risk. Neuropsychological testing is especially valuable in mild TBI to assess cognitive deficits and monitor recovery when structural imaging is normal.

The primary goal of traumatic brain injury (TBI) management is to prevent secondary brain injury through early stabilization, maintenance of adequate cerebral perfusion, and prompt treatment of life-threatening complications. Initial management follows the principles of airway, breathing, and circulation (ABC), emphasizing airway protection, adequate oxygenation and ventilation, prevention of hypoxia, hypotension, and abnormal carbon dioxide levels, monitoring and control of intracranial pressure (ICP), and early neurosurgical consultation when indicated. Mild TBI is typically managed with neurological assessment, selective CT imaging guided by validated clinical decision rules, short-term observation when appropriate, and discharge with clear follow-up instructions, while emerging biomarkers such as glial fibrillary acidic protein (GFAP) may improve patient triage. In contrast, moderate-to-severe TBI requires intensive care with rapid physiological stabilization, continuous neurological monitoring, ICP management, timely surgical intervention for intracranial lesions, and adherence to evidence-based guidelines to optimize oxygenation, blood pressure, and cerebral perfusion, thereby improving neurological outcomes.

"Traumatic Brain Injury Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traumatic Brain Injury pipeline landscape is provided which includes the disease overview and Traumatic Brain Injury treatment guidelines. The assessment part of the report embraces, in depth Traumatic Brain Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traumatic Brain Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Traumatic Brain Injury Pipeline Report Highlights

The Traumatic Brain Injury companies and academics are working to assess challenges and seek opportunities that could influence Traumatic Brain Injury R&D. The therapies under development are focused on novel approaches to treat/improve Traumatic Brain Injury.

Traumatic Brain Injury Emerging Drugs Analysis

This segment of the Traumatic Brain Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Traumatic Brain Injury Emerging Drugs

Autologous HB-adMSCs: Hope Biosciences LLC

Autologous HB-adMSCs are adipose-derived mesenchymal stem cells obtained from the patient and expanded for therapeutic use, acting mainly through immunomodulation, anti-inflammatory effects, and paracrine signaling that supports neural repair and reduces neuroinflammation after TBI. These cells may also promote tissue regeneration and support the recovery of damaged brain function. In traumatic brain injury, HB-adMSCs are currently being evaluated in clinical studies, with Phase I safety studies completed and Phase II trials ongoing to assess efficacy and neurological outcomes.

BBT-101: BEYOND Barriers Therapeutics

BBT-101 is a first-in-class intranasal formulation of N-acetylcysteine (NAC) being developed for the treatment of mild and moderate traumatic brain injury (TBI). Designed to enhance brain glutathione levels and reduce neuroinflammation, oxidative stress, and cerebral edema, BBT-101 utilizes a patented nose-to-brain delivery platform that bypasses first-pass metabolism, enabling faster onset, improved brain targeting, and substantially greater bioavailability than oral NAC. Developed through the FDA's 505(b)(2) regulatory pathway, the therapy builds on NAC's well-established safety profile while introducing an optimized delivery approach for early intervention following TBI. BBT-101 is currently being evaluated in an investigator-sponsored Phase Ib/IIa clinical trial in emergency department patients with concussion/TBI, with an additional study planned in collegiate athletes. The program has also received support from the U.S. Special Operations Command (SOCOM), the NFL Players Association (NFLPA), and the U.S. Department of Defense to advance next-generation concussion therapeutics.

ST266: Noveome Biotherapeutics

ST266 is a first-of-its-kind, multi-targeted, noncellular biologic being developed by Noveome Biotherapeutics with the potential to improve patient outcomes across a range of challenging diseases and conditions in ophthalmology, neurology, dermatology, and beyond. Derived from the secretome of amnion-derived multipotent progenitor cells, ST266 comprises a complex mixture of cytokines, growth factors, and extracellular vesicles that collectively exert anti-inflammatory, neuroprotective, and regenerative effects. In TBI, the therapy is designed to modulate multiple biological pathways involved in secondary injury processes, including neuroinflammation, oxidative stress, and neuronal cell death. Unlike conventional single-target therapies, ST266 offers a multi-mechanistic approach and can be administered via non-invasive routes such as intranasal delivery, enabling direct targeting of the central nervous system. A drug master file has been submitted to the FDA, supporting all ST266 IND applications. According to the company’s pipeline, the drug is in the Phase I stage of its development for the treatment of TBI.

MP201: Mitochon Pharmaceuticals

MP201 is a mitochondrial-targeted small molecule prodrug developed by Mitochon Pharmaceuticals to treat neurodegenerative and neurotraumatic conditions. MP201 works by modulating mitochondrial physiology through mild increases in cellular energy expenditure, which leads to improved mitochondrial calcium handling, reduced production of ROS, enhanced mitophagy, and activation of neuroprotective signaling pathways such as cAMP, CREB, and BDNF, ultimately promoting neuronal survival and repair. The drug is being developed primarily for TBI. MP201 is currently in the preclinical stage.

Foralumab: Tiziana Life Sciences

Foralumab is a fully human anti-CD3 monoclonal antibody designed to modulate the immune system by binding to the CD3 receptor on T cells, thereby inducing Tregs and suppressing inflammatory responses. This mechanism helps reduce neuroinflammation, which is a key driver in central nervous system disorders. Intranasal Foralumab demonstrated the ability to reduce brain inflammation and improve functional recovery in preclinical models, primarily through IL-10–dependent Tregs-mediated modulation of microglia. Currently, Foralumab is in the preclinical stage of development for TBI.

Further product details are provided in the report……..

Traumatic Brain Injury Drug Therapeutic Assessment

This segment of the report provides insights about the different Traumatic Brain Injury drugs segregated based on following parameters that define the scope of the report, such as:

Major Traumatic Brain Injury Players in Traumatic Brain Injury

There are approx. 40+ key companies which are developing the therapies for Traumatic Brain Injury. The companies which have their Traumatic Brain Injury drug candidates in the most advanced stage, i.e. Phase II include, Hope Biosciences LLC.

Traumatic Brain Injury Clinical Trial Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Traumatic Brain Injury Drug Route of Administration

Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Traumatic Brain Injury Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Traumatic Brain Injury Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Traumatic Brain Injury Pipeline Development Activities

The Traumatic Brain Injury clinical Trial analysis report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Traumatic Brain Injury therapeutic drugs key players involved in developing key drugs.

Traumatic Brain Injury Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traumatic Brain Injury drugs.

Traumatic Brain Injury Pipeline Report Insights

• Traumatic Brain Injury Pipeline Analysis
• Traumatic Brain Injury Therapeutic Assessment
• Traumatic Brain Injury Unmet Needs
• Impact of Traumatic Brain Injury Drugs

Traumatic Brain Injury Pipeline Report Assessment

• Traumatic Brain Injury Pipeline Product Profiles
• Traumatic Brain Injury Therapeutic Assessment
• Traumatic Brain Injury Pipeline Assessment
• Traumatic Brain Injury Inactive drugs assessment
• Traumatic Brain Injury Market Unmet Needs

Traumatic Brain Injury Report Assessment Dashboard Inclusions (Available with Site-license)

• Clinical Trial Analysis
• Clinical Trial Design Analysis
• Sponsor and Geographical Analysis

Traumatic Brain Injury Clinical Trial Analysis

The report comprises of comparative assessment of clinical trial analysis (by status, development stage, therapy area, enrolled participants by age, study completion year, end point status).

Traumatic Brain Injury Clinical Trial Design Analysis

The report comprises of comparative assessment of clinical trial design analysis (by allocation, interventional model, enrolled participants by status, masking).

Sponsor and Geographical Analysis

The report comprises of comparative assessment of sponsor and geographical analysis (by top sponsors, developmental stage, clinical trials sponsored by countries, therapies by countries).

Key Questions Answered In The Traumatic Brain Injury Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Traumatic Brain Injury drugs?
• How many Traumatic Brain Injury drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traumatic Brain Injury?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Traumatic Brain Injury therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Traumatic Brain Injury and their status?
• What are the key designations that have been granted to the emerging drugs?

Traumatic Brain Injury Key Players

• Biomed Industries
• SHINKEI Therapeutics
• Oragenics
• Dompé farmaceutici
• BEYOND Barriers Therapeutics
• Grey Matter Health
• GryPhon Bio
• Alpha Cognition
• Alcamena
• Applied Cognition
• Silver Creek Pharmaceuticals
• Azevan Pharmaceuticals
• NOVEOME Biotherapeutics, Inc.
• Neuroplast
• Addex therapeutics
• Ischemix, Inc.
• AlzeCure Pharma AB
• Matricelf
• AivoCode
• International Stemcell Corporation
• Mitochon Pharmaceuticals
• NervGen Pharma
• Tiziana Life Sciences

Traumatic Brain Injury Key Products

• NA-731
• MR-301
• ONP-002
• Research Program
• BBT-101
• AP-188
• OWL-1410
• ALPHA-1062
• ASCT-83
• ACX-02
• SCP776
• SRX251
• ST266
• Neuro-cell
• Diplaglurant
• CMX-2043
• ACD856
• Research Program
• AC01
• ISC-hpNSC
• MP201
• NVG-291
• Foralumab